UP!

PPHM $4.22

PPHM target price
4.22
0
0
Peregrine Pharmaceuticals, Inc
Type
Public
Traded as NASDAQ: PPHM,NASDAQ: PPHMP
Industry Pharmaceuticals
Founded 1981
Headquarters Tustin, California, United States
Key people
Steven W. King
(President and CEO)
Revenue Increase US$ 26.781 million (2015)
Operating income
Decrease US$ -50.499 million (2015)
Net income
Decrease US$ -50.358 million (2015)
Total assets Increase US$ 97.464 million (2015)
Total equity Increase US$ 97.646 million (2015)
Number of employees
Increase 215 (April 30, 2015)
Website www.peregrineinc.com

Peregrine Pharmaceuticals, Inc. is a publicly-traded American biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials as potential cancer treatments and diagnostic agents. As of 2016 their lead product candidate was bavituximab. It also has a revenue-generating subsidiary, Avid Bioservices, which is a contract manufacturing organization that provides services to Peregrine and to other companies.

Peregrine was founded in 1981.

In 2002 Peregrine established a wholly owned subsidiary, Avid Bioservices, a contract manufacturing organization that provides cGMP development and biomanufacturing services for both Peregrine and outside customers. In 2015 Avid had revenues of about $27 million, about 80% of which came under contract from Halozyme Therapeutics.

Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C. The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans.

I-PGN650 is a phosphatidylserine-targeting F(ab')2 fully human monoclonal antibody fragment joined to the PET imaging radio-isotope iodine-124 being developed to obtain medical images of cancer.

Cotara (I-chTNT-1/B) is a chimeric monoclonal antibody against DNA-histone H1 complex called TNT-1, conjugated to the radioisotope iodine-131. As of 2016 Peregrine was developing it for Glioblastoma multiforme; it has been granted orphan status in Europe and the US.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-06-04 Reiterated Rating FBR & Co. Buy $1.00
2016-06-04 Reiterated Rating FBR & Co Buy $1.00
2016-05-20 Reiterated Rating FBR & Co. Outperform $1.00
2016-04-23 Reiterated Rating FBR & Co. Buy
2016-03-04 Lower Price Target FBR & Co. Outperform $3.50 to $1.00
2016-02-28 Reiterated Rating FBR & Co. Outperform $3.50 to $1.00
2016-02-26 Downgrade Roth Capital Buy to Neutral $3.00 to $0.50
2016-01-22 Reiterated Rating Roth Capital Buy $3.00
2016-01-14 Reiterated Rating FBR & Co. Outperform $3.50
2016-01-12 Initiated Coverage FBR & Co. Buy
2015-12-14 Reiterated Rating Noble Financial Buy $5.00
2015-10-30 Reiterated Rating FBR & Co. Outperform
2015-08-25 Reiterated Rating Roth Capital Buy $5.00
2015-07-16 Reiterated Rating Roth Capital Buy
2015-07-16 Initiated Coverage Noble Financial Buy $5.00
2015-06-10 Set Price Target Roth Capital Buy $5.00
2015-06-01 Reiterated Rating MLV & Co. Buy $3.50
2015-04-20 Set Price Target Roth Capital Buy $5.00
2015-03-13 Set Price Target MLV & Co. Buy $3.50
2014-07-15 Reiterated Rating Roth Capital Buy
2014-03-11 Reiterated MLV & Co Buy $2.50 to $3.50
2014-03-11 Reiterated
2014-03-11 Boost Price Target MLV & Co. Buy $2.50 to $3.50
2014-01-17 Lower Price Target JPMorgan Chase & Co. $12.00 to $9.50
2012-09-27 Resumed MLV & Co Buy $4.50 to $2
2011-08-30 Initiated JMP Securities Mkt Outperform $5
2016-06-04 Reiterated Rating FBR & Co. Buy $1.00
2016-06-04 Reiterated Rating FBR & Co Buy $1.00
2016-05-20 Reiterated Rating FBR & Co. Outperform $1.00
2016-04-23 Reiterated Rating FBR & Co. Buy
2016-03-04 Lower Price Target FBR & Co. Outperform $3.50 to $1.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
LYTLE PAUL J Chief Financial Officer 0.10%  (184038) PPHM /
SWARTZ ERIC S 0.07%  (126000) PPHM /
Fussey Shelley PM VP, Intellectual Property 0.06%  (110475) PPHM /
Bamforth Mark R 0.06%  (100000) PPHM /
McComb Joel 0.03%  (50000) PPHM /
CARLEONE JOSEPH 0.02%  (44445) APFC / PPHM / SXT /
KING STEVEN W President & CEO 0.02%  (34646) PPHM /
Shan Joseph VP Clinical/Regulatory Affairs 0.01%  (16187) PPHM /
Masten Jeffrey L. V.P. Quality 0.01%  (12498) PPHM /